Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials
Source : https://www.tandfonline.com/doi/abs/10.1080/17512433.2022.2106968?journalCode=ierj20
Abstract The risk of bleeding associated with Bruton's tyrosine kinase inhibitor (BTKi) monotherapy remains to be understood. This systematic review aims to evaluate BTKi monotherapy related bleeding risk. PubMed, Embase, and CENTRAL were searched up to December 5, 2021. We included randomized controlled trials (RCTs) comparing BTKi monotherapy with control drugs or placebo, or comparing different BTKi monotherapies.
Conclusions: Ibrutinib and acalabrutinib (vs. control drugs or placebo) have a higher risk of bleeding and overall bleeding, respectively. Limited evidence suggests that ibrutinib (vs. acalabrutinib) significantly increases overall bleeding risk, but the differences are not observed in other comparisons.